Skip to main content
. 2020 Jan 3;99(1):e18462. doi: 10.1097/MD.0000000000018462

Figure 4.

Figure 4

The correlation of the serum IL-26 level with IL-17 level in CHB patients. A. The serum IL-17 level was measured at weeks 0 (baseline), 12, 24, 36, and 52 post LdT therapy in CHB patients. B. The correlation analysis was performed between the serum levels of IL-26 and IL-17 in CHB patients at baseline. Data are expressed as mean ± SD.P < .05, ∗∗P < .01; n = 30.